Jennifer N Durham

List of Publications by Citations

17 papers	3,961 citations	13 h-index	17 g-index
17 ext. papers	5,403 ext. citations	13.4 avg, IF	4.27 L-index

#	Paper	IF	Citations
17	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, **2017**, 357, 409-413	333	3274
16	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. *Science*, **2019**, 364, 485-491	33.3	228
15	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. *JCI Insight*, **2018**, 3,	9.9	128
14	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. *Clinical Cancer Research*, **2019**, 25, 7024-7034	12.9	48
13	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. *Clinical Cancer Research*, **2020**, 26, 3578-3588	12.9	36
12	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. *Journal of Clinical Oncology*, **2019**, 37, 3546-3555	2.2	32
11	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 3182-3192	12.9	31
10	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. *Clinical Cancer Research*, **2019**, 25, 5250-5259	12.9	29
9	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. *Clinical Cancer Research*, **2020**, 26, 5129-5139	12.9	28
8	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 **2019**, 7, 40		28
7	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. *Cancer Medicine*, **2020**, 9, 1485-1494	4.8	25
6	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. *Cancer Immunology Research*, **2019**, 7, 1574-1579	12.5	21
5	Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. *Nature Cancer*, **2021**, 2, 891-903	15.4	18
4	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. *Cancer Cell*, **2021**, 39, 973-988.e9	23	13
3	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2021**, 27, 1278-1286	12.9	11
2	A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. *Cancer*, **2019**, 125, 2837-2845	6.4	8
1	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. *Oncotarget*, **2020**, 11, 1929-1941	3.3	3